Hancock Mark sold $9.4M of PACS

Hancock Mark sold 186,696 shares of PACS Group, Inc. (PACS) at an average of $50.45 ($50.38–$51.44, $9.42M total) across 2 trades on 2026-11-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hancock Mark
Published Nov 4, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PACS
Bearish
medium confidence
Mentioned
$PACS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACSBearishLow
01

Why it matters

The disclosed sale represents a $9.4M reduction in insider holdings, which may affect investor perception.

02

Market read

Insider sale could lead to short-term price decline; traders may watch for price reaction.

03

What to watch

Potential tax planning or diversification motives for the insider.

Relevance 5/10Novelty 6/10Timing: after-hours filing

Background

SEC Form 4 filing discloses insider transactions; required for directors and large shareholders.

Company-level read

Ticker impact

$PACSBearishMedium confidence
Context

Director and 10% owner Hancock Mark sold 186,696 shares for $9.4M via a Form 4 filing.

Expected impact

likely downward pressure as market prices in the insider sale

Evidence & confidence

A large insider sale by a director can be interpreted as lack of confidence, prompting short-term sell pressure.

Market effects

Minimal impact on the broader sector; primarily company-specific.

US market only.

Low

Counterpoint

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Hancock Mark

    Director and 10% owner of PACS Group, Inc.

  • PACS Group, Inc.

    Provider of patient access solutions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PACSMedAI 8/10

What PACS Group (PACS) Said on Its Q3 Earnings Call

PACS Group reported 196 mature, 90 ramping, and 35 new skilled nursing facilities with occupancy ranging from 76.2% to 93.1%. The company acquired 32 Florida and 10 Texas skilled nursing operations post-quarter. PACS raised its 2026 revenue outlook to $5.95B-$6.05B and adjusted EBITDA to $685M-$695M, citing strength in existing operations and new acquisitions. Operating cash flow was $583.1M for the first nine months of 2026, with $707.4M in available liquidity.

$PACSHighAI 8/10

PACS Group Inc (PACS) (Q3 2026) Earnings Call Highlights: Revenue Tops

PACS Group Inc (NYSE:PACS) reported Q3 2026 revenue growth of 6.4%, with adjusted EBITDA up 33.6% to $175.7M. The company raised full-year guidance, citing strong occupancy and skilled mix improvements. PACS also highlighted a robust acquisition pipeline and integration plans for 31 Eduro facilities. Challenges include lower metrics at newly acquired facilities and ongoing government investigations.

$PACSHigh

Why is PACS stock surging today?

PACS Group Inc (PACS) stock rose 6.0% in after-hours trading after beating Q3 2026 earnings and revenue estimates. The company also raised its full-year 2026 Adjusted EBITDA and revenue guidance. Analysts maintain a 'Moderate Buy' rating with an average price target of $58.80. The surge was driven by company-specific news.